U.S. markets close in 3 minutes
  • S&P 500

    4,193.15
    -39.45 (-0.93%)
     
  • Dow 30

    34,768.09
    -9.67 (-0.03%)
     
  • Nasdaq

    13,422.63
    -329.61 (-2.40%)
     
  • Russell 2000

    2,223.15
    -48.48 (-2.13%)
     
  • Crude Oil

    64.85
    -0.05 (-0.08%)
     
  • Gold

    1,838.10
    +6.80 (+0.37%)
     
  • Silver

    27.45
    -0.01 (-0.04%)
     
  • EUR/USD

    1.2145
    -0.0024 (-0.19%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • GBP/USD

    1.4134
    +0.0145 (+1.03%)
     
  • USD/JPY

    108.7710
    +0.1890 (+0.17%)
     
  • BTC-USD

    55,638.46
    -1,687.88 (-2.94%)
     
  • CMC Crypto 200

    1,480.47
    -80.83 (-5.18%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    29,518.34
    +160.52 (+0.55%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Frequency Therapeutics, Inc. (FREQ) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 5, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ:FREQ). Investors who purchased Frequency securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/freq.

The investigation concerns whether Frequency and certain of its officers and/or directors have violated federal securities laws.

On or around October 2, 2019, Frequency conducted its initial public offering ("IPO"), selling 6,000,000 shares of common stock priced at $14.00 per share. On March 23, 2021, Frequency issued a press release announcing topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). Frequency disclosed that "[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo." On this news, Frequency's stock price fell $28.30 per share, or 77.98%, to close at $7.99 per share on March 23, 2021.

If you are aware of any facts relating to this investigation, or purchased Frequency shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/freq. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/638441/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Frequency-Therapeutics-Inc-FREQ-Investigation